Arcturus Therapeutics (ARCT) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Arcturus Therapeutics Revenue Highlights

Latest Revenue (Y)

$157.75M

Latest Revenue (Q)

$41.67M

Main Segment (Y)

Collaboration Revenue

Arcturus Therapeutics Revenue by Period

Arcturus Therapeutics Revenue by Year

Date	Revenue	Change
2023-12-31	$157.75M	-23.33%
2022-12-31	$205.75M	1564.82%
2021-12-31	$12.36M	29.56%
2020-12-31	$9.54M	-54.12%
2019-12-31	$20.79M	31.97%
2018-12-31	$15.75M	21.20%
2017-12-31	$13.00M	100.00%
2016-12-31	-	100.00%
2015-12-31	-	100.00%
2014-12-31	-	100.00%
2013-12-31	-	100.00%
2012-12-31	-	100.00%
2011-12-31	-	-

Arcturus Therapeutics generated $157.75M in revenue during NA 2023, up -23.33% compared to the previous quarter, and up 1001.38% compared to the same period a year ago.

Arcturus Therapeutics Revenue by Quarter

Date	Revenue	Change
2024-09-30	$41.67M	-9.36%
2024-06-30	$45.98M	41.04%
2024-03-31	$32.60M	15.55%
2023-12-31	$28.21M	-34.96%
2023-09-30	$43.38M	353.49%
2023-06-30	$9.56M	-88.00%
2023-03-31	$79.73M	-50.18%
2022-12-31	$160.05M	1097.17%
2022-09-30	$13.37M	-50.66%
2022-06-30	$27.09M	416.65%
2022-03-31	$5.24M	-9.49%
2021-12-31	$5.79M	137.75%
2021-09-30	$2.44M	21.79%
2021-06-30	$2.00M	-5.92%
2021-03-31	$2.13M	-4.96%
2020-12-31	$2.24M	-4.07%
2020-09-30	$2.33M	0.47%
2020-06-30	$2.32M	-12.24%
2020-03-31	$2.65M	-10.85%
2019-12-31	$2.97M	-10.55%
2019-09-30	$3.32M	-67.32%
2019-06-30	$10.15M	133.40%
2019-03-31	$4.35M	-42.59%
2018-12-31	$7.58M	121.36%
2018-09-30	$3.42M	43.46%
2018-06-30	$2.39M	0.80%
2018-03-31	$2.37M	-81.79%
2017-12-31	$13.00M	294.36%
2017-09-30	$3.30M	-12.36%
2017-06-30	$3.76M	100.00%
2017-03-31	-	100.00%
2016-12-31	-	100.00%
2016-09-30	-	100.00%
2016-06-30	-	100.00%
2016-03-31	-	100.00%
2015-12-31	-	100.00%
2015-09-30	-	100.00%
2015-06-30	-	100.00%
2015-03-31	-	100.00%
2014-12-31	-	100.00%
2014-09-30	-	100.00%
2014-06-30	-	100.00%
2014-03-31	-	100.00%
2013-12-31	-	100.00%
2013-09-30	-	100.00%
2013-06-30	-	100.00%
2013-03-31	-	100.00%
2012-12-31	-	100.00%
2012-09-30	-	100.00%
2012-06-30	-	-

Arcturus Therapeutics generated $41.67M in revenue during Q3 2024, up -9.36% compared to the previous quarter, and up 435.68% compared to the same period a year ago.

Arcturus Therapeutics Revenue Breakdown

Arcturus Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22
Collaboration Revenue	$157.75M	$205.75M

Arcturus Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Collaboration Revenue (100.00%).

Quarterly Revenue by Product

Product/Service	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Mar 23	Jun 19
Grant	$2.86M	$3.88M	$5.41M	$954.00K	$556.00K	-	-
Collaboration Revenue	$38.81M	$45.98M	$32.60M	$78.02M	$9.56M	$79.73M	-
Other Collaboration Revenue	-	-	-	-	-	-	$3.60M

Arcturus Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Collaboration Revenue (93.14%), and Grant (6.86%).

Arcturus Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
AMLX	Amylyx Pharmaceuticals	$380.79M	$416.00K
BEAM	Beam Therapeutics	$377.71M	$14.27M
CRSP	CRISPR Therapeutics	$370.00M	$602.00K
BPMC	Blueprint Medicines	$249.38M	$128.18M
ARCT	Arcturus Therapeutics	$157.75M	$41.67M
ACLX	Arcellx	$110.32M	$26.03M
FATE	Fate Therapeutics	$63.53M	$6.77M
NTLA	Intellia Therapeutics	$36.27M	$9.11M
CRBU	Caribou Biosciences	$34.48M	$3.46M
STOK	Stoke Therapeutics	$8.78M	$4.89M
PLRX	Pliant Therapeutics	$1.58M	-
FIXX	Q32 Bio	$1.16M	-
BCEL	Atreca	$770.00K	$80.00K
KRTX	Karuna Therapeutics	$654.00K	-
BDTX	Black Diamond Therapeutics	-	-
GOSS	Gossamer Bio	-	$9.48M
DAWN	Day One Biopharmaceuticals	-	$20.07M
MDGL	Madrigal Pharmaceuticals	-	$62.17M
BMEA	Biomea Fusion	-	-
ETNB	89bio	-	-
AKRO	Akero Therapeutics	-	-
FDMT	4D Molecular Therapeutics	-	-

ARCT Revenue FAQ

What is Arcturus Therapeutics’s yearly revenue?

Arcturus Therapeutics's yearly revenue for 2023 was $157.75M, representing a decrease of -23.33% compared to 2022. The company's yearly revenue for 2022 was $205.76M, representing an increase of 1564.82% compared to 2021. ARCT's yearly revenue for 2021 was $12.36M, representing an increase of 29.56% compared to 2020.

What is Arcturus Therapeutics’s quarterly revenue?

Arcturus Therapeutics's quarterly revenue for Q3 2024 was $41.67M, a -9.36% decrease from the previous quarter (Q2 2024), and a -3.93% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $45.98M, a 41.04% increase from the previous quarter (Q1 2024), and a 380.67% increase year-over-year (Q2 2023). ARCT's quarterly revenue for Q1 2024 was $32.6M, a 15.55% increase from the previous quarter (Q4 2023), and a -59.11% decrease year-over-year (Q1 2023).

What is Arcturus Therapeutics’s revenue growth rate?

Arcturus Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 1176.38%, and for the last 5 years (2019-2023) was 658.81%.

What are Arcturus Therapeutics’s revenue streams?

Arcturus Therapeutics's revenue streams in c 23 are Collaboration Revenue

What is Arcturus Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Arcturus Therapeutics was Collaboration Revenue. This segment made a revenue of $157.75M, representing 100.00% of the company's total revenue.